Litracef-CV Tablet is a combination antibiotic formulation containing Cefuroxime 500 mg and Clavulanic Acid 125 mg, designed for the treatment of a broad spectrum of bacterial infections. Cefuroxime, a second-generation cephalosporin, exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefuroxime by preventing the degradation of the antibiotic by beta-lactamase enzymes produced by resistant bacteria. This synergistic combination is effective against various gram-positive and gram-negative pathogens, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media. Litracef-CV is indicated for patients requiring robust antimicrobial therapy where resistance to beta-lactam antibiotics is suspected or confirmed. The tablet should be administered as prescribed by a healthcare professional, typically with food to improve absorption and reduce gastrointestinal discomfort. Caution is advised in patients with a history of hypersensitivity to cephalosporins or penicillins. Adverse effects may include gastrointestinal disturbances, allergic reactions, and, rarely, hematological abnormalities. Proper adherence to the prescribed dosage and duration is essential to prevent resistance development and ensure therapeutic success.